<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">  <head>    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>    <title>All Interactions with Didanosine</title><link rel="stylesheet" href="css/insite.css" type="text/css"/><link rel="stylesheet" href="css/layout.css" type="text/css"/><link rel="stylesheet" href="css/topNav.css" type="text/css"/><!-- jquery javascript --><script type="text/javascript" src="script/jquery/load.js"><!--  --></script><script type="text/javascript" src="app-js/jquery.scrollTo.js"> </script><script type="text/javascript" src="app-js/jquery.cycle.js"> </script><script type="text/javascript" language="JavaScript">
        function openWindow(url,name){
            newWin = window.open(url,name,'status,toolbar,menubar,resizable,scrollbars,left=20,top=20,width=650,height=600')
            newWin.focus()
        }

        function openXWindow(url,name){
            newXWin = window.open(url,name)
            newXWin.focus()
        }

		/* BASED ON NEC DEMO.XML */
		   // REVEAL HIDDEN LOGIC QUESTION
				function branchNext (event) {
					$.log("BRANCHNEXT() :  enter");
					var n = $(this).children("input:checked").size();

					if (n)   {
						 var reveal = "." + $($(this).children("input:checked")).attr("name") + "-" + $($(this).children("input:checked")).val();

						 $(reveal).removeClass("hidden").addClass("question-revealed");
					}
			   }

		// HIDE TO-BE-REVEALED LOGIC QUESTIONS
			$(document).ready(function() { hideLogicQuestions($(document).children()[0]) });

			function hideLogicQuestions (element) {
				$.log("hideLogicQuestions() : enter");
				$(".hidden-question").each(function() {
					$(this).addClass("hidden").removeClass("question-revealed");
				});
		   }
		/* END FROM NEC DEMO.XML */


			function expand(event)
			{
				var id = $(event.target).attr("query");
				var section = $("#" + id);

				/* CLOSE ALL SECTIONS AND RESET BUTTONS
				$(".expandable", section).addClass("hidden");
				$(".expand", section).removeClass("hidden");
				$(".collapse", section).addClass("hidden");
				$(".expandAll", section).removeClass("hidden");
				$(".collapseAll", section).addClass("hidden");
				*/

				// OPEN SPECIFIED SECTION AND UPDATE ITS BUTTONS
				section.removeClass("hidden");
				$(this).addClass("hidden");
				$(this).siblings(".collapse").removeClass("hidden");

				// $(this).siblings(".expandAll").addClass("hidden");
				// $(this).siblings(".collapseAll").removeClass("hidden");
			}
			function collapse(event)
			{
				var id = $(event.target).attr("query");
				var section = $("#" + id);

				section.addClass("hidden");
				$(this).addClass("hidden");
				$(this).siblings(".expand").removeClass("hidden");

				$(this).siblings(".collapseAll").addClass("hidden");
				$(this).siblings(".expandAll").removeClass("hidden");
			}

			function expandAll(event)
			{
				var id = $(event.target).attr("query");
				var section = $("#" + id);

				section.removeClass("hidden");
				$(".expandable", section).removeClass("hidden");
				$(this).addClass("hidden");

				$(this).siblings(".expand").addClass("hidden");
				$(this).siblings(".collapse").removeClass("hidden");
				$(this).siblings(".collapseAll").removeClass("hidden");

				$(".expand", section).addClass("hidden");
				$(".collapse", section).removeClass("hidden");
			}
			function collapseAll(event)
			{
				var id = $(event.target).attr("query");
				var section = $("#" + id);

				section.addClass("hidden");
				$(".expandable", section).addClass("hidden");
				$(this).addClass("hidden");

				$(this).siblings(".collapse").addClass("hidden");
				$(this).siblings(".expand").removeClass("hidden");
				$(this).siblings(".expandAll").removeClass("hidden");

				$(".expand", section).removeClass("hidden");
				$(".collapse", section).addClass("hidden");
			}


			// connect the correct fuctions
			function sconnect(element) {
				$(".reveal-question", element).click(branchNext);

				$(".expand", element).click(expand);
				$(".expandAll", element).click(expandAll);
				$(".collapse", element).click(collapse);
				$(".collapseAll", element).click(collapseAll);
			}

			// load method for adding connections
			$(document).ready(function() {
				sconnect($(document).children()[0])
			 });

			 $(document).ready(function(){
			 $('.carousel ul').cycle({'prev':'.previous','next':'.next','play':'.play','pause':'.pause'});
			 $(".carousel-hidden").each(function () {
			 $(this).removeClass("carousel-hidden");
			 });
			 });


		</script><!--*********************************************************
    *************************************************************
    REPLACE GOOGLE ANALYTICS SCRIPT BEFORE PUBLISHING TO LIVESITE
    You can find the script in google-analytics.js **************
    *************************************************************
    **********************************************************--><script type="text/javascript">
   
     var _gaq = _gaq || [];
     _gaq.push(['_setAccount', 'UA-19627862-1']);
     _gaq.push(['_trackPageview']);
   
     (function() {
       var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
       ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
       var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);
     })();
   
</script></head><body><div class="floatpage"><div id="ucsf"><a href="http://ucsf.edu/"><img src="images/masthead/ucsf.gif" alt="University of California, San Francisco Logo"/></a><p>University of California, San Francisco | <a href="http://www.ucsf.edu/about-ucsf/">About UCSF</a> | <a href="http://www.ucsf.edu/ucsf/search">Search UCSF</a> | <a href="http://www.ucsfhealth.org/">UCSF Medical Center</a></p></div><div id="header"><div style="float:left;"><a href="InSite" style="display:block;"><img src="images/masthead/splash-logo-top.gif" alt="HIV InSite"/></a><h1 class="site-description" style="clear:both; width: 475px;">Comprehensive, up-to-date information on HIV/AIDS treatment and prevention from the University of California San Francisco</h1></div><div class="site-sub-navigation"><a href="InSite">Home</a> | <a href="InSite?page=pb-00-00">Patient/Public</a> | <a href="InSite?page=Audio">Audio</a> | <a href="InSite?page=News">News</a> | <a href="InSite?page=Links">Links</a></div><div class="sitesearch"><form action="search" method="get" id="search"><input type="hidden" name="page" value="sr-00-00"/><input type="hidden" name="post" value="1"/><label for="SearchEntry">Search</label><input type="text" size="28" name="SearchEntry" id="SearchEntry" aria-label="Search"/><input type="submit" id="I1" value="Search" style="margin-left: 5px;"/></form></div><div id="site-navigation"><ul><li class="site-navigation"><a href="InSite?page=KB">Knowledge Base</a></li><li class="site-navigation"><a href="InSite?page=Treatment">Treatment</a></li><li class="site-navigation"><a href="InSite?page=Prevention">Prevention</a></li><li class="site-navigation"><a href="InSite?page=Policy">Policy Analysis</a></li><li class="site-navigation"><a href="InSite?page=cr-00-00">Global Response</a></li></ul></div></div><div id="content-target"><div><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td align="right"><font face="Arial, Helvetica" size="-2"><a href="http://hivinsite.ucsf.edu/InSite">Home</a> &gt; <a href="http://hivinsite.ucsf.edu/InSite?page=Treatment">Treatment</a> &gt; <a href="InSite?page=ar-00-02">Interactions</a></font></td></tr><tr><td><img alt="" src="images/transparent.gif" border="0" height="10" width="1"/></td></tr></tbody></table><div class="pgtitle">Database of Antiretroviral Drug Interactions</div><img alt="" src="images/greyline.gif"/><br/><p style="margin-top:0;padding-top:0;" class="kbrsec1">All Interactions with Didanosine (Videx)</p><table class="datatable" width="100%"><thead><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Didanosine</th><th>Effect on Drug Levels</th><th>Effect on Didanosine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr></thead><tr><td valign="top" width="10%">Allopurinol<sup><a href="#286">286</a>, <a href="#84">84</a>, <a href="#19">19</a></sup><div>(Zyloprim)</div></td><td valign="top">300 mg QD x 7 days</td><td valign="top">400 mg (buffered formulation) x 1 dose</td><td valign="top">Not studied</td><td valign="top">Didanosine AUC: increased 113-122%; Cmax: increased 69-116%</td><td valign="top">Increased didanosine effects (pancreatitis, neuropathy)</td><td valign="top">Inhibition of presystemic metabolism by allopurinol</td><td valign="top"><p>Consider reducing didanosine dose by 50%</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Amprenavir<sup><a href="#60">60</a></sup><div>(APV)(Agenerase)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">May decrease amprenavir bioavailability</td><td valign="top">-</td><td valign="top">Decreased amprenavir effects</td><td valign="top">Decreased amprenavir absorption</td><td valign="top"><p>Separate didanosine and amprenavir doses by at least 1 hour</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Amprenavir<sup><a href="#117">117</a></sup><div>(APV)(Agenerase)</div></td><td valign="top">600 mg BID on days 1-4 and 15-18</td><td valign="top">2-200 mg (tablets) QD</td><td valign="top">No significant change</td><td valign="top">Not studied</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Amprenavir<sup><a href="#117">117</a></sup><div>(APV)(Agenerase)</div></td><td valign="top">600 mg BID on days 1-4 and 15-18</td><td valign="top">400 mg (enteric coated capsules) QD</td><td valign="top">No significant change</td><td valign="top">Not studied</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Amprenavir<sup><a href="#127">127</a></sup><div>(APV)(Agenerase)</div></td><td valign="top">600 mg BID x 4 days</td><td valign="top">400 mg QD (buffered and enteric coated) x 4 days</td><td valign="top">No significant effect (with either didanosine formulation)</td><td valign="top">Not studied</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Didanosine</th><th>Effect on Drug Levels</th><th>Effect on Didanosine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Atazanavir<sup><a href="#152">152</a>, </sup><div>(ATV)(Reyataz)</div></td><td valign="top">300 mg with ritonavir 100 mg QD</td><td valign="top">400 mg (enteric coated capsule) QD with food</td><td valign="top">Atazanavir AUC: no significant change; Cmax: no significant change; Ritonavir AUC: no significant change; Cmax: no significant change</td><td valign="top">Didanosine AUC: decreased 34%; Cmax: decreased 38%; Cmin: increased 25%</td><td valign="top">Decreased didanosine effects</td><td valign="top">Reduced didanosine absorption due to presence of food</td><td valign="top"><p>Administer didanosine EC and atazanavir at different times</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Atazanavir<sup><a href="#124">124</a></sup><div>(ATV)(Reyataz)</div></td><td valign="top">400 mg QD with food</td><td valign="top">250 mg EC x 1 dose</td><td valign="top">Atazanavir AUC: decreased 26%; Cmax: decreased 24%</td><td valign="top">Didanosine AUC: no significant change (AUC comparable to that of didanosine 400 mg QD without tenofovir)</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Atazanavir<sup><a href="#152">152</a>, </sup><div>(ATV)(Reyataz)</div></td><td valign="top">400 mg QD with food</td><td valign="top">400 mg (enteric coated capsule) QD with food</td><td valign="top">No significant change</td><td valign="top">Didanosine AUC: decreased 34%; Cmax: decreased 36%</td><td valign="top">Decreased didanosine effects</td><td valign="top">Reduced didanosine absorption due to presence of food</td><td valign="top"><p>Administer didanosine EC and atazanavir at different times</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Atazanavir<sup/><div>(ATV)(Reyataz)</div></td><td valign="top">400 mg QD x 1 (given 1 hour after stavudine and didanosine)</td><td valign="top">200 mg (buffered tabs) x 1 dose</td><td valign="top">No significant change</td><td valign="top">Not studied</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Atazanavir<sup><a href="#122">122</a></sup><div>(ATV)(Reyataz)</div></td><td valign="top">400 mg x 1 dose</td><td valign="top">Also dosed with stavudine</td><td valign="top">Atazanavir Cmax: decreased 89%; AUC: decreased 87%</td><td valign="top">Not studied</td><td valign="top">Decreased atazanavir effects</td><td valign="top">- </td><td valign="top"><p>Dose adjustment not established</p><p class="warn"><b> </b></p></td></tr><tr><td valign="top" width="10%">Atazanavir<sup/><div>(ATV)(Reyataz)</div></td><td valign="top">400 mg x 1 dose (given simultaneously with stavudine and didanosine)</td><td valign="top">200 mg (buffered tabs) x 1 dose</td><td valign="top">Atazanavir AUC: decreased 87%; Cmin: decreased 84%; Cmax: decreased 89%</td><td valign="top">No significant change</td><td valign="top">Decreased atazanavir effects</td><td valign="top">Altered gastric pH decreasing atazanavir absorption</td><td valign="top"><p>Administer didanosine tablets on an empty stomach and 2 hours before or 1 hour after food or atazanavir</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Didanosine</th><th>Effect on Drug Levels</th><th>Effect on Didanosine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Buprenorphine<sup><a href="#441">441</a></sup><div>(Suboxone)(Buprenex)</div></td><td valign="top">16 mg QD</td><td valign="top">400 mg QD</td><td valign="top">No significant change</td><td valign="top">- </td><td valign="top">- </td><td valign="top">- </td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr><td valign="top" width="10%">Cidofovir<sup><a href="#371">371</a></sup><div>(Vistide)</div></td><td valign="top">3 mg/kg IV (with probenecid) on days 1 and 8</td><td valign="top">200 mg (buffered formulation) BID on days 2-8</td><td valign="top">No significant change</td><td valign="top">Didanosine AUC: increased 60%</td><td valign="top">Increased didanosine effects</td><td valign="top">Possible inhibition of renal tubular secretion by probenecid or cidofovir</td><td valign="top"><p>Dose adjustment not established</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Ciprofloxacin<sup><a href="#326">326</a>, <a href="#84">84</a>, <a href="#19">19</a></sup><div>(Cipro)</div></td><td valign="top">750 mg Q12H x 3 days</td><td valign="top">200 mg (buffered formulation) Q12H x 3 days</td><td valign="top">Ciprofloxacin AUC: decreased 26% when ciprofloxacin is dosed 2 hours before or 6 hours after didanosine tablets. Ciprofloxacin AUC: decreased 15-fold (with simultaneous didanosine dosing)</td><td valign="top">Didanosine AUC: decreased 16%; Cmax: decreased 28%</td><td valign="top">Decreased ciprofloxacin effects</td><td valign="top">Chelation and adsorption of ciprofloxacin by divalent/trivalent cations contained in didanosine buffer</td><td valign="top"><p>Consider didanosine EC or administer didanosine tablets/suspension 6 hours prior to or 2 hours after ciprofloxacin administration</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Ciprofloxacin<sup><a href="#84">84</a></sup><div>(Cipro)</div></td><td valign="top">750 mg x 1 dose</td><td valign="top">400 mg (enteric coated capsule) x 1 dose</td><td valign="top">No significant change</td><td valign="top">Not studied</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Dapsone<sup><a href="#327">327</a>, <a href="#84">84</a></sup><div>(others)(Avlosulfon)</div></td><td valign="top">100 mg x 1 dose</td><td valign="top">200 mg (buffered formulation) Q12H x 14 days</td><td valign="top">No significant change</td><td valign="top">No significant change</td><td valign="top">- </td><td valign="top">- </td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr><td valign="top" width="10%">Delavirdine<sup><a href="#19">19</a></sup><div>(DLV)(Rescriptor)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">Delavirdine AUC: decreased 20%</td><td valign="top">Not studied</td><td valign="top">Decreased delavirdine effects</td><td valign="top">-</td><td valign="top"><p>Consider didanosine EC or administer delavirdine at least 1 hour prior to didanosine tablets/suspension</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Didanosine</th><th>Effect on Drug Levels</th><th>Effect on Didanosine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Delavirdine<sup><a href="#84">84</a>, <a href="#19">19</a>, <a href="#88">88</a></sup><div>(DLV)(Rescriptor)</div></td><td valign="top">400 mg TID x 28 days</td><td valign="top">125 or 250 mg BID x 28 days</td><td valign="top">Delavirdine AUC: decreased 19%; Cmax: decreased 32%</td><td valign="top">Didanosine AUC: decreased 21%; Cmax: decreased 20%</td><td valign="top">- </td><td valign="top">Decreased didanosine and delavirdine absorption</td><td valign="top"><p>Separate didanosine and delavirdine doses by at least 1 hour</p><p class="warn"><b> </b></p></td></tr><tr><td valign="top" width="10%">Delavirdine<sup><a href="#84">84</a>, <a href="#19">19</a></sup><div>(DLV)(Rescriptor)</div></td><td valign="top">400 mg x 1 dose</td><td valign="top">125 or 200 mg (buffered formulation) Q12H</td><td valign="top">Delavirdine AUC: decreased 32%; Cmax: decreased 53%</td><td valign="top">Not studied</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>Dose adjustment not established</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Delavirdine<sup><a href="#84">84</a>, <a href="#19">19</a></sup><div>(DLV)(Rescriptor)</div></td><td valign="top">400 mg x 1 dose (administered 1 hr before didanosine)</td><td valign="top">125 or 200 mg (buffered formulation) Q12H</td><td valign="top">Delavirdine AUC: increased 20%; Cmax: increased 18%</td><td valign="top">Not studied</td><td valign="top">- </td><td valign="top">- </td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr><td valign="top" width="10%">Efavirenz<sup><a href="#143">143</a></sup><div>(EFV)(Sustiva)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">Potential early virologic failure</td><td valign="top">-</td><td valign="top"><p>Use caution when coadministering tenofovir, didanosine and either efavirenz or nevirapine in treatment-naive patients</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Etravirine<sup><a href="#405">405</a></sup><div>(ETR)(Intelence)</div></td><td valign="top">-</td><td valign="top">400 mg QD</td><td valign="top">Etravirine Cmax: increased 16%</td><td valign="top">No significant change</td><td valign="top">- </td><td valign="top">- </td><td valign="top"><p>No dose adjsutment </p><p class="warn"><b> </b></p></td></tr><tr><td valign="top" width="10%">Food<sup><a href="#228">228</a></sup><div/></td><td valign="top">High-fat meal, light meal, yogurt or apple sauce</td><td valign="top">400 mg (enteric coated capsule) x 1 dose</td><td valign="top">-</td><td valign="top">Didanosine AUC(with high-fat meal): decreased 19%; AUC(with light meal): decreased 27%; AUC(with yogurt): decreased 20%; AUC(with applesauce): decreased 18%; AUC(1 hour before meal): decreased 24%; AUC (2 hours after meal): no significant change</td><td valign="top">Decreased didanosine EC effects(reduction in bioavailability by 20-25% when given with any food)</td><td valign="top">Possible increase in gastric acidity affecting didanosine EC bioavailability</td><td valign="top"><p>Administer didanosine EC at least 1 hour prior to or 2 hours after any food</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Didanosine</th><th>Effect on Drug Levels</th><th>Effect on Didanosine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Ganciclovir<sup><a href="#233">233</a></sup><div>(Cytovene)</div></td><td valign="top">1000 mg PO Q8H</td><td valign="top">buffered formulation</td><td valign="top">Ganciclovir AUC: increased 115%; Cmax: incrased 116% (when separated by 2 hours); Ganciclovir AUC: increased 107%; Cmax: increased 108% (when taken simultaneously)</td><td valign="top">Not studied</td><td valign="top">Increased ganciclovir effects</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Ganciclovir<sup><a href="#84">84</a>, <a href="#19">19</a></sup><div>(Cytovene)</div></td><td valign="top">1000 mg PO Q8H</td><td valign="top">200 mg (buffered formulation) Q12H</td><td valign="top">Ganciclovir AUC: decreased 21%</td><td valign="top">Didanosine AUC: increased 111%</td><td valign="top">Decreased ganciclovir effects; increased didanosine effects</td><td valign="top">Decreased oral ganciclovir absorption due to decreased gastric acidity resulting from antacid buffer contained within didanosine tablets/suspension</td><td valign="top"><p>Consider didanosine EC or do not give didanosine tablets/suspension concurrently or within 2 hours of oral ganciclovir administration</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Indinavir<sup><a href="#19">19</a>, <a href="#83">83</a></sup><div>(IDV)(Crixivan)</div></td><td valign="top">-</td><td valign="top">Buffered formulation</td><td valign="top">Indinavir AUC: decreased 84%</td><td valign="top">Not studied</td><td valign="top">Decreased indinavir effects</td><td valign="top">Decreased indinavir absorption due to decreased gastric acidity resulting from antacid buffer contained within didanosine tablets/suspension</td><td valign="top"><p>Consider didanosine EC or administer indinavir at least 1 hour prior to didanosine tablets/suspension</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Indinavir<sup><a href="#84">84</a>, <a href="#19">19</a></sup><div>(IDV)(Crixivan)</div></td><td valign="top">800 mg x 1 dose</td><td valign="top">400 mg (enteric coated capsule) x 1 dose</td><td valign="top">No significant change</td><td valign="top">Not studied</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Indinavir<sup><a href="#84">84</a>, <a href="#19">19</a></sup><div>(IDV)(Crixivan)</div></td><td valign="top">800 mg x 1 dose</td><td valign="top">200 mg (buffered formulation) x 1 dose</td><td valign="top">Not studied</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Indinavir<sup><a href="#84">84</a>, <a href="#19">19</a></sup><div>(IDV)(Crixivan)</div></td><td valign="top">800 mg x 1 dose (administered 1 hour before didanosine)</td><td valign="top">200 mg (buffered formulation) x 1 dose</td><td valign="top">Not studied</td><td valign="top">Didanosine AUC: decreased 17%; Cmax: no significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Didanosine</th><th>Effect on Drug Levels</th><th>Effect on Didanosine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Indinavir<sup><a href="#16">16</a>, <a href="#19">19</a>, <a href="#20">20</a></sup><div>(IDV)(Crixivan)</div></td><td valign="top">-</td><td valign="top">Buffered formulation</td><td valign="top">Indinavir AUC: decreased 84%</td><td valign="top">Not studied</td><td valign="top">Decreased indinavir effects</td><td valign="top">Decreased indinavir absorption</td><td valign="top"><p>Take drugs at least one hour apart</p><p class="warn"><i>Alternative Agents</i>: <br/><b>Didanosine enteric coated</b></p></td></tr><tr><td valign="top" width="10%">Itraconazole<sup><a href="#280">280</a>, <a href="#19">19</a></sup><div>(Sporanox)(Sporanox)</div></td><td valign="top">200 mg (capsule) x 1 dose</td><td valign="top">300 mg (buffered formulation) x 1 dose</td><td valign="top">Itraconaxole Cmax: undetectable</td><td valign="top">Not studied</td><td valign="top">Decreased itraconazole effects</td><td valign="top">Decreased itraconazole absorption due to decreased gastric acidity resulting from antacid buffer contained within didanosine tablets/suspension</td><td valign="top"><p>Administer itraconazole capsules at least 2 hours after didanosine tablets/suspension</p><p class="warn"><i>Alternative Agents</i>: <br/><b>Itraconazole solution</b></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Ketoconazole<sup><a href="#285">285</a>, <a href="#19">19</a></sup><div>(Nizoral)</div></td><td valign="top">200 mg QD x 4 days</td><td valign="top">375 mg (buffered formulation) BID x 4 days</td><td valign="top">No significant change</td><td valign="top">No significant change</td><td valign="top">Possibly decreased didanosine effects</td><td valign="top">Decreased ketoconazole absorption due to decreased gastric acidity resulting from antacid buffer contained within didanosine tablets/suspension</td><td valign="top"><p>Consider didanosine EC or administer ketoconazole at least 2 hours prior to didanosine tablets/suspension</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Ketoconazole<sup><a href="#84">84</a></sup><div>(Nizoral)</div></td><td valign="top">200 mg x 1 dose</td><td valign="top">400 mg (enteric coated capsule) x 1 dose</td><td valign="top">No significant change</td><td valign="top">Not studied</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Loperamide<sup><a href="#84">84</a></sup><div>(Imodium, Imodium A-D)(Imodium)</div></td><td valign="top">4 mg Q6H x 1 day</td><td valign="top">300 mg (buffered formulation) x 1 dose</td><td valign="top">Not studied</td><td valign="top">Didanosine AUC: no significant change; Cmax: decreased 23%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Lopinavir/ritonavir<sup><a href="#78">78</a></sup><div>(LPV/r)(Kaletra)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">Decreased lopinavir/ritonavir absorption</td><td valign="top"><p>Take didanosine 1 hour before or 2 hours after lopinavir/ritonavir</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Didanosine</th><th>Effect on Drug Levels</th><th>Effect on Didanosine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Methadone<sup><a href="#203">203</a></sup><div>(Dolophine)(Dolophine)</div></td><td valign="top">-</td><td valign="top">200 mg (buffered formulation) BID</td><td valign="top">Not studied</td><td valign="top">Didanosine AUC: decreased 57%; Cmax: decreased 44%</td><td valign="top">Decreased didanosine effects</td><td valign="top">Decreased didanosine bioavailability by methadone</td><td valign="top"><p>Dose adjustment not established</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Methadone<sup><a href="#84">84</a></sup><div>(Dolophine)(Dolophine)</div></td><td valign="top">stable</td><td valign="top">200 mg (buffered formulation) x 1 dose</td><td valign="top">Not studied</td><td valign="top">Didanosine AUC: decreased 41%; Cmax: decreased 59%</td><td valign="top">Decreased didanosine effects</td><td valign="top">Decreased didanosine bioavailability by methadone</td><td valign="top"><p>Dose adjustment not established</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Metoclopramide<sup><a href="#84">84</a></sup><div>(Reglan)(Reglan)</div></td><td valign="top">10 mg x 1 dose</td><td valign="top">300 mg (buffered formulation) x 1 dose</td><td valign="top">Not studied</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Nelfinavir<sup><a href="#19">19</a></sup><div>(NFV)(Viracept)</div></td><td valign="top">750 mg x 1 dose</td><td valign="top">200 mg x 1 dose</td><td valign="top">No significant change</td><td valign="top">Not studied</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Nelfinavir<sup><a href="#19">19</a>, <a href="#24">24</a></sup><div>(NFV)(Viracept)</div></td><td valign="top">750 mg x 1 dose</td><td valign="top">200 mg (buffered formulation) x 1 dose</td><td valign="top">No significant change</td><td valign="top">Not studied</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Nevirapine<sup><a href="#95">95</a></sup><div>(NVP)(Viramune)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">No significant change</td><td valign="top">Not studied</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Didanosine</th><th>Effect on Drug Levels</th><th>Effect on Didanosine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Nevirapine<sup><a href="#143">143</a></sup><div>(NVP)(Viramune)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">Potential early virologic failure</td><td valign="top">-</td><td valign="top"><p>Use caution when coadministering tenofovir, didanosine and either efavirenz or nevirapine in treatment-naive patients</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Ranitidine<sup><a href="#244">244</a>, <a href="#84">84</a></sup><div>(Zantac)(Zantac)</div></td><td valign="top">150 mg x 1 dose</td><td valign="top">375 mg (sachet) x 1 dose</td><td valign="top">Ranitidine AUC: decreased 16%; Cmax: no significant change</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">Inhibition of gastric acid slightly enhancing didanosine bioavailablity by reducing acid degradation</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Ribavirin<sup><a href="#237">237</a>, <a href="#238">238</a>, <a href="#84">84</a>, <a href="#19">19</a></sup><div>(Rebetol, Virazole)</div></td><td valign="top">600 mg QD x 8 weeks</td><td valign="top">200 mg (tablets) BID x 12 weeks</td><td valign="top">No significant change</td><td valign="top">No significant change</td><td valign="top">Increased risk of mitochondrial toxicity</td><td valign="top">Ribavirin has been shown in vitro to increase intracellular triphosphate levels of didanosine.</td><td valign="top"><p>Information from a case series suggests that combining didanosine and ribavirin increases mitochondrial toxicity by five fold. Avoid combination if possible. Monitor closely and discontinue if signs of mitochondrial toxicity develop.</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Rifabutin<sup><a href="#84">84</a></sup><div>(Mycobutin)(Mycobutin)</div></td><td valign="top">300 mg or 600 mg QD x 12 days</td><td valign="top">167 mg or 250 mg (buffered formulation) Q12H x 12 days</td><td valign="top">Not studied</td><td valign="top">Didanosine AUC: no significant change; Cmax: increased 17%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Rilpivirine<sup><a href="#567">567</a></sup><div>(RPV)(Edurant)</div></td><td valign="top">150 mg QD</td><td valign="top">400 mg delayed release cap taken 2 hours before rilpivirine</td><td valign="top">No significant change</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary; Administer didanosine on an empty stomach and at least 2 hours before or at least 4 hours after rilpivirine (which must be administered with a meal).</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Ritonavir<sup><a href="#54">54</a>, <a href="#55">55</a></sup><div>(RTV)(Norvir)</div></td><td valign="top">600 mg BID</td><td valign="top">200 mg (tablets) BID</td><td valign="top">Not studied</td><td valign="top">Didanosine AUC: decreased 15%; Cmax: decreased 15%</td><td valign="top">Decreased didanosine effects</td><td valign="top">Formulation incompatibility</td><td valign="top"><p>Separate didanosine and ritonavir administration by at least 2.5 hours</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Didanosine</th><th>Effect on Drug Levels</th><th>Effect on Didanosine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Ritonavir<sup><a href="#84">84</a></sup><div>(RTV)(Norvir)</div></td><td valign="top">600 mg Q12H x 4 days</td><td valign="top">200 mg (buffered formulation) Q12H x 4 days</td><td valign="top">No significant change</td><td valign="top">Didanosine AUC: no significant change; Cmax: decreased 16%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Stavudine<sup><a href="#84">84</a>, <a href="#19">19</a></sup><div>(d4T)(Zerit)</div></td><td valign="top">40 mg Q12H x 4 days</td><td valign="top">100 mg (buffered formulation) x 4 days</td><td valign="top">Stavudine AUC: no significant change; Cmax: increased 17%</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Stavudine<sup><a href="#86">86</a>, <a href="#87">87</a></sup><div>(d4T)(Zerit)</div></td><td valign="top">40 mg Q12H x 9 doses</td><td valign="top">100 mg Q12H x 9 doses</td><td valign="top">No significant change</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Sulfamethoxazole<sup><a href="#84">84</a></sup><div/></td><td valign="top">1000 mg x 1 dose</td><td valign="top">200 mg (buffered formulation) x 1 dose</td><td valign="top">No significant change</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Tenofovir disoproxil fumarate<sup><a href="#143">143</a></sup><div>(TDF)(Viread)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">Potential early virologic failure</td><td valign="top">-</td><td valign="top"><p>Use caution when coadministering tenofovir, didanosine and either efavirenz or nevirapine in treatment-naive patients</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Tenofovir disoproxil fumarate<sup><a href="#96">96</a></sup><div>(TDF)(Viread)</div></td><td valign="top">300 mg QD</td><td valign="top">400 mg QD (enteric coated) x 7 days (given without food)</td><td valign="top">Not studied</td><td valign="top">Didanosine AUC: increased 48%; Cmax: increased 28%</td><td valign="top">Increased didanosine effects</td><td valign="top">Possible shared elimination pathway</td><td valign="top"><p>Reduce didanosine dose to 250 mg QD when used with tenofovir</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Didanosine</th><th>Effect on Drug Levels</th><th>Effect on Didanosine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Tenofovir disoproxil fumarate<sup><a href="#96">96</a></sup><div>(TDF)(Viread)</div></td><td valign="top">300 mg QD</td><td valign="top">400 mg QD (enteric coated) x 7 days (given with food)</td><td valign="top">-</td><td valign="top">-</td><td valign="top">Increased didanosine effects</td><td valign="top">Possible shared elimination pathway</td><td valign="top"><p>Reduce didanosine dose to 250 mg QD when used with tenofovir</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Tenofovir disoproxil fumarate<sup><a href="#96">96</a>, <a href="#102">102</a></sup><div>(TDF)(Viread)</div></td><td valign="top">300 mg QD</td><td valign="top">400 mg (enteric coated capsule) x 1 dose</td><td valign="top">No significant change</td><td valign="top">Didanosine AUC: increased 48% (fasted); Cmax: increased 48% (fasted)Didanosine AUC: increased 60% (fed); Cmax: increased 64% (fed)</td><td valign="top">Increased didanosine effects</td><td valign="top">Possible shared elimination pathway</td><td valign="top"><p>Reduce didanosine dose to 250 mg QD when used with tenofovir</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Tenofovir disoproxil fumarate<sup><a href="#96">96</a></sup><div>(TDF)(Viread)</div></td><td valign="top">300 mg QD</td><td valign="top">250 mg or 400 mg (buffered formulation) QD x 7 days</td><td valign="top">No significant change</td><td valign="top">Didanosine AUC: increased 44%; Cmax: increased 28%</td><td valign="top">Increased didanosine effects</td><td valign="top">Possible shared elimination pathway</td><td valign="top"><p>Reduce didanosine dose to 250 mg QD when used with tenofovir</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Tenofovir disoproxil fumarate<sup><a href="#97">97</a>, <a href="#96">96</a></sup><div>(TDF)(Viread)</div></td><td valign="top">300 mg QD x 7 days</td><td valign="top">400 mg (buffered formulation) QD x 7 days</td><td valign="top">No significant change</td><td valign="top">Didanosine AUC: increased 44%; Cmax: increased 28%</td><td valign="top">Increased didanosine effects</td><td valign="top">Possible shared elimination pathway</td><td valign="top"><p>Reduce didanosine dose to 250 mg QD when used with tenofovir</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Tenofovir disoproxil fumarate<sup><a href="#103">103</a></sup><div>(TDF)(Viread)</div></td><td valign="top">300 mg QD x 9 days</td><td valign="top">250 mg QD (enteric coated) x 1 (given with food, without food and staggered by 2 hours)</td><td valign="top">No significant change</td><td valign="top">Didanosine AUC: no significant change (fed); Cmax: no significant change; Didanosine AUC: no significant change (staggered); Cmax: no significant change (staggered); Didanosine AUC: no significant change (fed); Cmax: decreased 29% (fed)All values compared to 400 mg QD (enteric coated) reference dose.</td><td valign="top">-</td><td valign="top">Possible shared elimination pathway</td><td valign="top"><p>Reduce didanosine dose to 250 mg QD when used with tenofovir</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Tipranavir<sup><a href="#154">154</a></sup><div>(TPV)(Aptivus)</div></td><td valign="top">1250 mg BID with 100 mg ritonavir BID x 42 doses</td><td valign="top">125 mg BID x 43 doses</td><td valign="top">-</td><td valign="top">Didanosine AUC: no significant change; Cmax: decreased 23%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary; separate didanosine formulations from tipranavir by 2 hours</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Didanosine</th><th>Effect on Drug Levels</th><th>Effect on Didanosine Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Tipranavir<sup><a href="#154">154</a></sup><div>(TPV)(Aptivus)</div></td><td valign="top">250 mg BID with 200 mg ritonavir BID</td><td valign="top">200 mg BID</td><td valign="top">-</td><td valign="top">Didanosine AUC: decreased 33%; Cmax: decreased 43%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary; separate didanosine formulations away from tipranavir by 2 hours</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Tipranavir<sup><a href="#154">154</a></sup><div>(TPV)(Aptivus)</div></td><td valign="top">500 mg BID with 100 mg ritonavir BID x 27 doses</td><td valign="top">400 mg x 1</td><td valign="top">Tipranavir AUC: no significant change; Cmax: increased 32%; Cmin: decreased 34%</td><td valign="top">Didanosine AUC: no significant change; Cmax: decreased 20%; Cmin: no significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Tipranavir<sup><a href="#154">154</a></sup><div>(TPV)(Aptivus)</div></td><td valign="top">750 mg BID with 100 mg ritonavir BID</td><td valign="top">200 mg BID</td><td valign="top">-</td><td valign="top">Didanosine AUC: no significant change; Cmax: decreased 24%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary; separate didanosine formulations from tipranavir by 2 hours</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Trimethoprim<sup><a href="#84">84</a>, <a href="#19">19</a></sup><div>(Trimpex)(Trimpex)</div></td><td valign="top">200 mg x 1 dose</td><td valign="top">200 mg (buffered formulation) x 1 dose</td><td valign="top">Trimethoprim AUC: no significant change; Cmax: decreased 22%</td><td valign="top">Didanosine AUC: no significant change; Cmax: increased 17%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Zidovudine<sup><a href="#84">84</a>, <a href="#19">19</a></sup><div>(AZT, ZDV)(Retrovir)</div></td><td valign="top">200 mg Q8H x 3 days</td><td valign="top">200 mg (buffered formulation) Q12H x 3 days</td><td valign="top">Zidovudine AUC: no significant change; Cmax: decreased 16.5%</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#bbbbbb"><td class="cellleft" colspan="8">"-" indicates that there are no data available
                
            </td></tr></table><table cellspacing="2" cellpadding="0" border="0"><tr><td valign="top" class="cellrightblue"><a name="16"> </a>16:</td><td class="cellleft">Crixivan [package insert]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; Oct 2005.</td></tr><tr><td valign="top" class="cellrightblue"><a name="19"> </a>19:</td><td class="cellleft">Videx [package insert]. Princeton, NJ: Bristol-Myers Squibb Co.; 2003.</td></tr><tr><td valign="top" class="cellrightblue"><a name="20"> </a>20:</td><td class="cellleft">Mummaneni V, Damle B, Kaul S, Knupp CA. Lack of effect of didanosine encapsulated enteric coated beadlet formulation on the pharmacokinetics of indinavir, ketoconazole, and ciprofloxacin in healthy subjects [abstract #1629]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sept 17-20; Toronto, Canada.</td></tr><tr><td valign="top" class="cellrightblue"><a name="24"> </a>24:</td><td class="cellleft">Viracept [package insert]. La Jolla, CA: Agouron Pharmaceuticals, Inc.; Sept 2004.</td></tr><tr><td valign="top" class="cellrightblue"><a name="54"> </a>54:</td><td class="cellleft">Cato A, Qian J, Hsu A, et al.  Pharmacokinetic interaction between ritonavir and didanosine when administered concurrently to HIV-infected patients.  J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:466-72.</td></tr><tr><td valign="top" class="cellrightblue"><a name="55"> </a>55:</td><td class="cellleft">Norvir [package insert]. North Chicago, IL: Abbott Laboratories, 2008.</td></tr><tr><td valign="top" class="cellrightblue"><a name="60"> </a>60:</td><td class="cellleft">Agenerase [package insert]. Research Triangle Park, NC: Glaxo Wellcome Inc; 2004.</td></tr><tr><td valign="top" class="cellrightblue"><a name="78"> </a>78:</td><td class="cellleft">Kaletra [package insert]. North Chicago, IL: Abbott Laboratories; Oct 2005.</td></tr><tr><td valign="top" class="cellrightblue"><a name="83"> </a>83:</td><td class="cellleft">Shelton MJ, et al. If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects. Animicrob Agents Chemother 2001;45:298-300.</td></tr><tr><td valign="top" class="cellrightblue"><a name="84"> </a>84:</td><td class="cellleft">Videx EC [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; Oct 2005.</td></tr><tr><td valign="top" class="cellrightblue"><a name="86"> </a>86:</td><td class="cellleft">Zerit [package insert]. Princeton, NJ: Bristol-Myers Squibb Immunology; Sept 2005.</td></tr><tr><td valign="top" class="cellrightblue"><a name="87"> </a>87:</td><td class="cellleft">Seifert RD, Stewart MB, Sramek JJ.  Pharmacokinetics of co-administered didanosine and stavudine in HIV-seropositive male patients.  Br J Clin Pharmacol 1994;38:405-10.</td></tr><tr><td valign="top" class="cellrightblue"><a name="88"> </a>88:</td><td class="cellleft">Rescriptor [package insert]. La Jolla, California: Agouron Pharmaceuticals, Inc; June 2001.</td></tr><tr><td valign="top" class="cellrightblue"><a name="95"> </a>95:</td><td class="cellleft">Viramune [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; Nov 2005.</td></tr><tr><td valign="top" class="cellrightblue"><a name="96"> </a>96:</td><td class="cellleft">Viread [package insert]. Foster City, CA: Gilead Sciences, Inc.; March 2006.</td></tr><tr><td valign="top" class="cellrightblue"><a name="97"> </a>97:</td><td class="cellleft">Kearney B, Flaherty J, Sayre J, et al. A multiple-dose, randomized, crossover, drug interaction study between tenofovir DF and lamivudine or didanosine [abstract #337]. 1st International AIDS Society Conference on HIV Treatment and Pathogenesis; 2001 July 8-11th; Buenos Aires, Argentina.</td></tr><tr><td valign="top" class="cellrightblue"><a name="102"> </a>102:</td><td class="cellleft">Kearney B, Damle B, Plummer A, et al. Pharmacokinetics evaluation of tenofovir DF and enteric-coated didanosine. Sixth International Congress on Drug Therapy in HIV Infection; 2002 November 17-21; Glasgow, United Kingdom.</td></tr><tr><td valign="top" class="cellrightblue"><a name="103"> </a>103:</td><td class="cellleft">Kearney BP, Isaacson E, Sayre J, et al. Didanosine and tenofovir DF drug-drug interaction: assessment of didanosine dose reduction [abstract #533]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 February 10-14; Boston, Massachusetts.</td></tr><tr><td valign="top" class="cellrightblue"><a name="117"> </a>117:</td><td class="cellleft">Shelton MJ, Giovanniello AG, Cloen D, et al. The effects of didanosine formulations on the pharmacokinetics of amprenavir [abstract #A-1826]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 September 27-30; Chicago, Illinois.</td></tr><tr><td valign="top" class="cellrightblue"><a name="122"> </a>122:</td><td class="cellleft">Omara E et al. BMS-232632: A summary of multiple dose pharmacokinetic, food effect and drug interaction studies in healthy subjects [abstract #504]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco, California.</td></tr><tr><td valign="top" class="cellrightblue"><a name="124"> </a>124:</td><td class="cellleft">Kaul S, Bassi K, Damle B, et al. Pharmacokinetic evaluation of the combination of atazanavir (ATV), enteric coated didanosine (ddI-EC), and tenofovir disoproxil fumarate (TDF) for a once-daily antiretroviral regimen [abstract #A-1616]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 September 14-17; Chicago, Illinois.</td></tr><tr><td valign="top" class="cellrightblue"><a name="127"> </a>127:</td><td class="cellleft">Shelton MJ, Giovanniello AA, Cloen D, et al. Effects of didanosine formulations on the pharmacokinetics of amprenavir. Pharmacotherapy 2003; 23: 835-42.</td></tr><tr><td valign="top" class="cellrightblue"><a name="143"> </a>143:</td><td class="cellleft">Bristol-Myers Squibb Company. Potential early virologic failure associated with the combination antiretroviral regimen of tenofovir disoproxil fumarate, didanosine and either efavirenz or nevirapine in HIV treatment-naive patients with high baseline viral loads. Dear Health Care Provider letter. November 2004.</td></tr><tr><td valign="top" class="cellrightblue"><a name="152"> </a>152:</td><td class="cellleft">Kaul S, Olszyk C, Ji P, et al. Pharmacokinetics of didanosine enteric coated capsules co-administered with atazanavir or atazanavir/ritonavir [abst. #648]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 February 22-25; Boston, Massachusetts.</td></tr><tr><td valign="top" class="cellrightblue"><a name="154"> </a>154:</td><td class="cellleft">Aptivus [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; Nov 2005.</td></tr><tr><td valign="top" class="cellrightblue"><a name="203"> </a>203:</td><td class="cellleft">Rainey PM, Friedland G, McCance-Katz EF, et al. Interaction of methadone with didanosine and stavudine. J Acquir Immune Defic Syndr 2000;24:241-8.</td></tr><tr><td valign="top" class="cellrightblue"><a name="228"> </a>228:</td><td class="cellleft">Damle BD, Yan J, Behr D, et al. Effect of food on oral bioavailability of didanosine from delayed release capsules containing enteric coated beads [abstract #A-499]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 December 16-19; Chicago, Illinois.</td></tr><tr><td valign="top" class="cellrightblue"><a name="233"> </a>233:</td><td class="cellleft">Cimoch PJ, Lavelle J, Pollard R, et al. Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:227-34.</td></tr><tr><td valign="top" class="cellrightblue"><a name="237"> </a>237:</td><td class="cellleft">Japour AJ, et al. A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. J Acquir Immune Defic Syndr Hum Retroviral 1996;13:235-46.</td></tr><tr><td valign="top" class="cellrightblue"><a name="238"> </a>238:</td><td class="cellleft">Fleischer R, Boxwell D, Sherman KE. Evidence suggesting mitochondrial toxicity in HIV/HCV co-infected patients receiving ribavirin and didanosine [abstract #763]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 February 10-14; Boston, Massachusetts.</td></tr><tr><td valign="top" class="cellrightblue"><a name="244"> </a>244:</td><td class="cellleft">Knupp CA, et al. Pharmacokinetic-interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus. Antimicrob Agents Chemother 1992;36:2075-9.</td></tr><tr><td valign="top" class="cellrightblue"><a name="280"> </a>280:</td><td class="cellleft">May DB, et al. Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers. Pharmacotherapy 1994;14:509-13.</td></tr><tr><td valign="top" class="cellrightblue"><a name="285"> </a>285:</td><td class="cellleft">Knupp CA, et al. Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropsoitive for the human immunodeficiency virus. J Clin Pharmacol 1993;33:912-17.</td></tr><tr><td valign="top" class="cellrightblue"><a name="286"> </a>286:</td><td class="cellleft">Liang D, Breaux K, Rodriguez-Barradas M, et al. Allopurinol increases didanosine (ddI) absorption in HIV-infected patients [abstract #A-498]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 December 16-19; Chicago, Illinois.</td></tr><tr><td valign="top" class="cellrightblue"><a name="326"> </a>326:</td><td class="cellleft">Knupp CA, et al. A multiple-dose pharmacokinetic interaction study between didanosine (Videx) and ciprofloxacin (Cipro) in male subjects seropositive for HIV but asymtomatic. Biopharm Drug Dispos 1997;18:65-77.</td></tr><tr><td valign="top" class="cellrightblue"><a name="327"> </a>327:</td><td class="cellleft">Sahai J, et al. Effects of the antacids in didanosine tablets on dapsone pharmacokinetics. Ann Intern Med 1995;123:584-7.</td></tr><tr><td valign="top" class="cellrightblue"><a name="371"> </a>371:</td><td class="cellleft">Luber A, Lalezari J, Rooney J, et al. Drug-drug interaction study with intravenous cidofovir (CDV) and either trimethoprim-sulfamethoxazole (TMP/SMX), didanosine (DDI) or fluconazole (FLU) in HIV-infected individuals. [abstract #A-1828]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 September 27-30; Chicago, Illinois.</td></tr><tr><td valign="top" class="cellrightblue"><a name="405"> </a>405:</td><td class="cellleft">Intelence [package insert]. Raritan, NJ: Tibotec Therapeutics; 2010.</td></tr><tr><td valign="top" class="cellrightblue"><a name="441"> </a>441:</td><td class="cellleft">Gruber VA, Baker J, Moody DE, et al. Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors didanosine, lamivudine and tenofovir [abstract A1-1306]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 September 12-15; San Francisco, California.</td></tr><tr><td valign="top" class="cellrightblue"><a name="567"> </a>567:</td><td class="cellleft">Edurant [package insert]. Raritan, NJ: Tibotec Therapeutics Inc.; May 2011.</td></tr></table></div></div><div class="footer"><p class="footerlinks"><a href="InSite?page=About">About</a> | <a href="InSite?page=SM">Site Map</a> | <a href="fb?page=Feedback">Feedback</a> | <a href="InSite?page=Subscribe">Subscribe</a> | <a href="InSite?page=Donate">Donate</a> | <a href="InSite?page=Disclaimer">Disclaimer</a></p><p class="copyright"><a href="http://chi.ucsf.edu/" target="OffSite"><img src="images/footer/chi.gif" alt="UCSF - Center for HIV Information"/></a> HIV InSite is a project of the UCSF Center for HIV Information. Copyright 2017, Regents of the University of California.</p></div></div></body></html>